» Articles » PMID: 35001081

Psychosocial Outcomes of Parents in Pediatric Haploidentical Transplant: Parental Hematopoietic Cell Donation As a Double-edged Sword

Overview
Specialty General Surgery
Date 2022 Jan 10
PMID 35001081
Authors
Affiliations
Soon will be listed here.
Abstract

Parents are increasingly used as donors for their child's haploidentical hematopoietic cell transplant, creating a dual role for parents that may increase the stress of caring for their ill child. Empiric research on the psychological adjustment of parental donors is lacking. We conducted a retrospective survey of parents (n = 136) whose child underwent transplant with a parental donor or a matched-unrelated donor, including both donor and nondonors, and both parents of survivors and bereaved. All parents completed standardized measures of quality of life, depression, anxiety, post-traumatic stress, and life satisfaction. Bereaved parents also completed measures of their grief response, while parents of survivors completed measures of the parent-child relationship. The overall sample reported psychological functioning near normative levels, but bereaved parents demonstrated significantly poorer outcomes across all measures. The effect of donor status differed by transplant outcome: for parents of survivors, donors reported better mental health than nondonors, but amongst bereaved parents, donors fared more poorly than nondonors. Bereaved donors reported greater difficulties with grief than nondonors. Results suggest that serving as donor can be a double-edged sword, acting as a protective factor when there is a successful outcome but a significant risk factor when the child does not survive.

References
1.
Passweg J, Baldomero H, Bader P, Bonini C, Duarte R, Dufour C . Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017; 52(6):811-817. PMC: 5467246. DOI: 10.1038/bmt.2017.34. View

2.
Watanabe M, Kanda J . Recent progress in haploidentical transplantation: is this the optimal choice for alternative donor transplantation?. Curr Opin Hematol. 2019; 26(6):406-412. DOI: 10.1097/MOH.0000000000000532. View

3.
Symons H, Zahurak M, Cao Y, Chen A, Cooke K, Gamper C . Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020; 4(16):3913-3925. PMC: 7448587. DOI: 10.1182/bloodadvances.2020001648. View

4.
Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D . Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion. Blood. 2017; 130(5):677-685. DOI: 10.1182/blood-2017-04-779769. View

5.
Mamcarz E, Madden R, Qudeimat A, Srinivasan A, Talleur A, Sharma A . Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplant. 2019; 55(5):929-938. PMC: 7202974. DOI: 10.1038/s41409-019-0750-7. View